Corvus Pharmaceuticals Inc
1.06 - 1.1
0.7501 - 9.54
Join Discuss about CRVS with like-minded investors
Ok ich lass es. keine Trades mehr. Intraday komm ich einfach auf keine CRVs die man da benötigen würde :)
46 Replies 14 👍 7 🔥
MIC CHRIS LEE WATCHLIST. Not many I really like its been slow and no follow through on the runners 1. CRVS multi day runner had a nice FGD we will see if we can get some continuation 2. IRNT they seem to be trying to push this up PR;s keep coming out with PT raises 3. OPAD still hovering the 10 line just watching 4. ATER still holding the multiday uptrend and reclaimed the 10 day and above the 20 day on the daily might make another bun at 20 line and the daily range is getting tighter 5. DNA is SPAC merger it has been on a multiday uptrend if it gets over the 14.25 ATH could see a nice move but this is not really the market for strong continuation so we will have to watch and see
47 Replies 8 👍 9 🔥
CRVS cracked $7 support from yesterday
100 Replies 13 👍 13 🔥
IU Watchlist - Sept 22: Main Watches: $MRIN will be everyone's watch tomorrow "obvious short" etc. that's fine I'll wait let everyone battle the obvious and then I'll look to come in. $LCID I am thinking we could go nuts $30-35 near term I always get a feel for something and it's the week after so I am thinking next week. We are either going $30-35 + blow off and craziness or we are going to reject REALLY hard and fail $3-4/share. Either I am okay with but for now I am still thinking we trap next two days as I said today. I don't think we go straight up as I said today looking to position on dips next two days and if I'm wrong that's fine too. I will ALSO look for shorts today and remind when it traps again that it was a trade and not building. KILLER trader very trader friendly today. $QS good vol higher better going to zone in here thinking big opportunity incoming. Better it builds better the opportunity. $UPSt starting to come on watch ideally $350 + parabolic ad I think we get a $30 pull back day. Two things to keep in mind: 1. Don't pre exhaust and 2. Don't underestimate the pull back day. Failed Follow Through: $RWLK nice fader AHs I thought about sticking around to fade it but - left - enough hours for one day. I am hopeful for a gap up should offered a BIG trade here. VERY nice opportunities today both on the long idea given for EOD ripper 2-3PM + as well as a few short trades thrown in there. As I wrote I sold MORE into close b/c it worked too well and was too strong and those are my rules. $AEMD looks like pump AHs after they accumulated all day. Looking to fade the gap once the exit comes in. $CEI sell pressure all day after the morning shove. Going to re position all dips we are on day 3 of 5 (as I went over in detail) so we should be close IMO if it can't bust higher remember $1.60 was key. $ATER nice levels today higher better and unwind is ideal - I still think this is SUPER crowded short side so patience is everything. $NNVC should provide a nice trade off open tomorrow - look left - more comments tomorrow. $EDSA higher better and unwind is ideal- great job today. Continuation: $CRVS lower better flush is ideal - AWESOME trade today. Great trade plan last night on scan worked to a tee. Scaled scaled scaled and sold into the parabolic move. Lower better let it consolidate a few days and will look to reposition. $LWLG trending well on daily - small position still. $GAME started in today seemed like a buyer was soaking in there today - someone positioning. $JZXN watch if we break $2.80 - every day decent seller at that level.
120 Replies 11 👍 11 🔥
Alex. mic. watchlist. ZIVO - Low hanging fruit. Ideally a r/g rejection or 5 rejection to short CRVS - Looking to short 6.00 / 6.20 / 6.40 lines with a 6.70 STOP. Nail and bal only VRDN - This is etb an ssr. This can and probably will be pumped. This is too difficult as it has too many red flags. So will likely avoid it EDSA - Low hanging fruit. This one has WIDE RANGE.. so use LESS SIZE to be able to scale in 10.00 / 10.50 / 11.00 / 11.50 lines at the open. Also is etb so NAIL AND BAIL ONLY NNVC - High volume pre market. This will likely be the hot chick of the day. AVOIDING this for now. Looking for easier setups BKYI - Looks to be topping out pre market so far, but will wait for the open. Ideally a morning push, STUFF, then we can look to short. More commentary at open -- The JumpStart Accelerator Course Is Now AVAILABLE!!!: https://myinvestingclub.com/jumpstart/
84 Replies 15 👍 6 🔥
Continuation (Long ideas): $CRVS this one is going to take time IMO - remember AEHR chart I shared? Check it - could play out like that may not. But - thought is $5.80s starts to firm up I'd look to scale if not I don't really see an edge. Huge squeeze out Friday, steady fail today .. trap squeezed everyone out today midday and trapped longs. Need to see this move set up a bit more before scaling/thinking where to "risk" etc. I had a few people ask me today when I traded that flush where I'd risk to - which is why I said if you bought as a day trade IMO after that .30+ rebound edge was gone and secondly for a big picture idea need to see if $5.80s firm up over next few days. Huge range both ways can't just come in and risk a dime or two. $HLBZ possible liquidity trap type trade off a flush tomorrow if it comes back it could come back in a fast way but - IMO be prepared to sell when it starts to thin up and go nuts. $GREE remember $500M ATM here - but thinking they put out a PR soon going to start to watch once they blow out all the long average down traders should offer a really nice trade 30-50% bounce before it fades off forever. The writing is on the wall on this one we talked about it and I've reminded everyone numerous times so don't turn into a baggy after the move happens.
141 Replies 8 👍 10 🔥
Next Dividend Date
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.
CEO: Richard Miller
HQ: 863 Mitten Rd Ste 102 Burlingame, 94010-1311 California